Protalix BioTherapeutics (PLX) EBITDA (2010 - 2026)

Protalix BioTherapeutics' EBITDA history runs 17 years deep, the most recent figure standing at $21.6 million for Q1 2026.

• In Q1 2026, EBITDA rose 667.25% year-over-year to $21.6 million; the TTM figure through Mar 2026 stood at $25.6 million (up 330.42% YoY), while the FY2025 annual figure was $287000.0, down 94.5% from the prior year.
• EBITDA was $21.6 million for Q1 2026 at Protalix BioTherapeutics, up from $51000.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $21.6 million in Q1 2026 to a low of -$5.6 million in Q4 2023.
• Historically, EBITDA has averaged $2.0 million across 5 years, with a median of -$1.9 million in 2022.
• The sharpest annual moves came in 2023 and 2026: EBITDA tumbled 174.91% in 2023, then surged 667.25% in 2026.
• A 5-year view of EBITDA shows it stood at $7.5 million in 2022, then sank by 174.91% to -$5.6 million in 2023, then soared by 234.34% to $7.5 million in 2024, then slumped by 99.32% to $51000.0 in 2025, then surged by 42154.9% to $21.6 million in 2026.
• The last three EBITDA figures came in at $21.6 million (Q1 2026), $51000.0 (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.